<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ZIPSOR- diclofenac potassium capsule, liquid filled </strong><br>Depomed, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Zipsor<span class="Sup">®</span>
      safely and effectively. See full prescribing information for Zipsor.
      <br><br>Zipsor<span class="Sup">®</span> (diclofenac potassium) Liquid Filled Capsule<br>Initial U.S.
      Approval: [1988] </div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING</span></h1>
<h1 class="Warning">
<span class="Bold Italics">See full prescribing information for
                              complete boxed warning</span>. </h1>
<ul class="Disc">
<li>
<span class="Underline">Cardiovascular Risk</span><ul class="Disc">
<li>NSAIDs may cause an increased risk of serious cardiovascular
                                    thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can
                                    be fatal. This risk may increase with duration of use. Patients
                                    with cardiovascular disease or risk factors for cardiovascular
                                    disease may be at greater risk. (<a href="#s9">5.1</a>) </li>
<li>Zipsor (diclofenac potassium) Liquid Filled Capsule is
                                    contraindicated for the treatment of perioperative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the
                                    setting of coronary artery bypass graft (CABG) surgery.
                                       (<a href="#s7">4</a>) </li>
</ul>
</li>
<li>
<span class="Underline">Gastrointestinal Risk</span><ul class="Disc"><li>NSAIDs cause an increased risk of serious gastrointestinal
                                    adverse events including, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation
                                    of the stomach or intestines, which can be fatal. These events
                                    can occur at any time during use and without warning symptoms.
                                    Elderly patients are at greater risk for serious
                                    gastrointestinal events. (<a href="#s10">5.2</a>)
                                 </li></ul>
</li>
</ul>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING</span></h1>
<h1 class="Warning">
<span class="Bold Italics">See full prescribing information for
                              complete boxed warning</span>. </h1>
<ul class="Disc">
<li>
<span class="Underline">Cardiovascular Risk</span><ul class="Disc">
<li>NSAIDs may cause an increased risk of serious cardiovascular
                                    thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can
                                    be fatal. This risk may increase with duration of use. Patients
                                    with cardiovascular disease or risk factors for cardiovascular
                                    disease may be at greater risk. (<a href="#s9">5.1</a>) </li>
<li>Zipsor (diclofenac potassium) Liquid Filled Capsule is
                                    contraindicated for the treatment of perioperative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the
                                    setting of coronary artery bypass graft (CABG) surgery.
                                       (<a href="#s7">4</a>) </li>
</ul>
</li>
<li>
<span class="Underline">Gastrointestinal Risk</span><ul class="Disc"><li>NSAIDs cause an increased risk of serious gastrointestinal
                                    adverse events including, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation
                                    of the stomach or intestines, which can be fatal. These events
                                    can occur at any time during use and without warning symptoms.
                                    Elderly patients are at greater risk for serious
                                    gastrointestinal events. (<a href="#s10">5.2</a>)
                                 </li></ul>
</li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Zipsor is a nonsteroidal anti-inflammatory drug indicated for
                           relief of mild to moderate <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">acute pain</span>. (<a href="#s2">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">The dosage is 25 mg four times a day. (<a href="#s3">2</a>) </p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li> 25 mg Liquid Filled Capsule (<a href="#s6">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to diclofenac. (<a href="#s7">4</a>)</li>
<li>History of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, or other allergic-type reactions
                              after taking aspirin or other NSAIDs. (<a href="#s7">4</a>)</li>
<li>Use during the perioperative period in the setting of coronary
                              artery bypass graft (CABG) surgery. (<a href="#s7">4</a>)</li>
<li>Zipsor contains gelatin and should not be given to patients with
                              known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to bovine protein. (<a href="#s7">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Serious and potentially fatal cardiovascular (CV) thrombotic
                              events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> can occur with NSAID
                              treatment. The lowest possible dose of Zipsor should be used in
                              patients with known CV disease or risk factors for CV disease.
                                 (<a href="#s9">5.1</a>) </li>
<li>NSAIDs, including diclofenac, can cause serious gastrointestinal
                              (GI) adverse events including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation.
                              Zipsor should be prescribed with caution in those with a prior history
                              of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> disease or <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>. (<a href="#s10">5.2</a>) </li>
<li>Elevation of one or more liver tests may occur during therapy with
                              diclofenac. Zipsor should be discontinued immediately if abnormal
                              liver tests persist or worsen. (<a href="#s11">5.3</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> can occur with NSAID treatment. Blood pressure should
                              be monitored closely during treatment with Zipsor. (<a href="#s12">5.4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> have been observed in some patients
                              taking NSAIDs. Zipsor should be used with caution in patients with
                              <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. (<a href="#s13">5.5</a>)</li>
<li>Long-term administration of NSAIDs can result in renal papillary
                              <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> and other <span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">renal injury</span>. Zipsor should be used with caution in
                              patients at greatest risk of this reaction, including the elderly,
                              those with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, liver dysfunction,
                              and those taking diuretics and ACE inhibitors. (<a href="#s14">5.6</a>) </li>
<li><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> may occur in patients with the aspirin
                              triad or in patients without prior exposure to Zipsor and should be
                              discontinued immediately if an <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> occurs.
                                 (<a href="#s15">5.7</a>)</li>
<li>NSAIDs can cause serious skin adverse events such as exfoliative
                              <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, Stevens - Johnson syndrome (SJS), and toxic epidermal
                              necrolysis (TEN), which can be fatal. Zipsor should be discontinued if
                              <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or other signs of local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span> occur. (<a href="#s16">5.8</a>) </li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><p class="Highlighta">Most common adverse reactions (incidence ≥ 1% of Zipsor
                           25 mg treated subjects) are gastrointestinal experiences including
                           <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>,
                           <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>.
                              (<a href="#s23">6</a>) <br><br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact
                              Depomed, Inc. at 1-866-458-6389 or FDA at 1-800-FDA-1088 or</span><span class="Bold Italics">www.fda.gov/medwatch.</span> </p></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Concomitant administration of diclofenac and aspirin is not
                              generally recommended because of the potential of increased adverse
                              effects including increased GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. (<a href="#s26">7.1</a>)</li>
<li>Concomitant use of anticoagulants and diclofenac have a risk of
                              serious GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> higher than users of either drug alone. (<a href="#s27">7.2</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>Pregnancy: Based on animal data, may cause fetal harm. Based on
                              human data, starting at 30 weeks gestation, Zipsor should be avoided
                              as premature closure of the ductus arteriosus in the fetus may occur.
                                 (<a href="#s17">5.9</a>, <a href="#s35">8.1</a>) </li>
<li>Nursing Mothers: Use with caution, as it is not known if diclofenac
                              is excreted in human milk. (<a href="#s38">8.3</a>)</li>
</ul></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 8/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS</a></h1>
<h1><a href="#section-1" class="toc">1. INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2. DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Initiating Therapy</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Non-Interchangeability with Other Formulations of Diclofenac</a></h2>
<h1><a href="#section-3" class="toc">3. DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4. CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5. WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Cardiovascular Thrombotic Events</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Gastrointestinal (GI) Effects – Risk of GI Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and
                        Perforation</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Hepatic Effects</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Renal Effects</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Adverse <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Pregnancy</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Corticosteroid Treatment</a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Masking of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></a></h2>
<h2><a href="#section-5.12" class="toc">5.12 Hematological Effects</a></h2>
<h2><a href="#section-5.13" class="toc">5.13 Use in Patients with Preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></a></h2>
<h2><a href="#section-5.14" class="toc">5.14 Monitoring</a></h2>
<h1><a href="#section-6" class="toc">6. ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Study Experience</a></h2>
<h1><a href="#section-7" class="toc">7. DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Aspirin</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Anticoagulants</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 ACE-inhibitors</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Diuretics</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Lithium</a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Methotrexate</a></h2>
<h2><a href="#section-7.7" class="toc">7.7 Cyclosporine</a></h2>
<h2><a href="#section-7.8" class="toc">7.8 Inhibitors or Substrates of Cytochrome P450 2C9 Other Considerations</a></h2>
<h1><a href="#section-8" class="toc">8. USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10. OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11. DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12. CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13. NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14. CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16. HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17. PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Cardiovascular Effects</a></h2>
<h2><a href="#section-15.2" class="toc">17.2 Gastrointestinal Effects</a></h2>
<h2><a href="#section-15.3" class="toc">17.3 Hepatotoxicity</a></h2>
<h2><a href="#section-15.4" class="toc">17.4 Adverse <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></a></h2>
<h2><a href="#section-15.5" class="toc">17.5 <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></a></h2>
<h2><a href="#section-15.6" class="toc">17.6 <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></a></h2>
<h2><a href="#section-15.7" class="toc">17.7 Effects During Pregnancy</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS</h1>
<p class="First"><span class="Bold">Cardiovascular Risk</span><br><br></p>
<ul class="Disc">
<li>
<span class="Bold">Nonsteroidal anti-inflammatory drugs (NSAIDs) may
                           increase the risk of serious cardiovascular (CV) thrombotic events,
                           <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. This risk may
                           increase with duration of use. Patients with cardiovascular disease or
                           risk factors for cardiovascular disease may be at greater risk [see
                           Warnings and Precautions (<a href="#s9">5.1</a>)].</span><br><br>
</li>
<li>
<span class="Bold">Zipsor is contraindicated for the treatment of
                           perioperative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft (CABG)
                           surgery [see Contraindications (<a href="#s7">4</a>)].</span><br><br>
</li>
</ul>
<p><span class="Bold">Gastrointestinal Risk</span><br><br></p>
<ul class="Disc"><li><span class="Bold">NSAIDs increase the risk of serious
                           gastrointestinal (GI) adverse reactions including, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration,
                           and perforation of the stomach or intestines, which can be fatal. These
                           events can occur at any time during use and without warning symptoms.
                           Elderly patients are at greater risk for serious gastrointestinal events
                           [see Warnings and Precautions (<a href="#s10">5.2</a>)].</span></li></ul>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s2"></a><a name="section-1"></a><p></p>
<h1>1. INDICATIONS AND USAGE</h1>
<p class="First">Zipsor is indicated for relief of mild to moderate <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">acute pain</span> in adults
                     (18 years of age or older).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s3"></a><a name="section-2"></a><p></p>
<h1>2. DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s4"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Initiating Therapy</h2>
<p class="First">For treatment of mild to moderate <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">acute pain</span>, the dosage is 25 mg
                           four times a day. Use the lowest effective dose for the shortest duration
                           consistent with individual patient treatment goals.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Non-Interchangeability with Other Formulations of Diclofenac</h2>
<p class="First">Different formulations of oral diclofenac are not bioequivalent
                           even if the milligram strength is the same. Therefore, it is not possible
                           to convert dosing from any other formulation of diclofenac to Zipsor. The
                           only approved dosing regimen for Zipsor is 25 mg four times a day.
                        </p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s6"></a><a name="section-3"></a><p></p>
<h1>3. DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Oral Liquid Filled Capsule 25 mg</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s7"></a><a name="section-4"></a><p></p>
<h1>4. CONTRAINDICATIONS</h1>
<p class="First">Zipsor is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>
                     (e.g., <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> and serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>) to diclofenac [see
                     Warnings and Precautions (<a href="#s15">5.7</a>, <a href="#s16">5.8</a>)]. </p>
<p>Zipsor is contraindicated in patients who have experienced <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>,
                     <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, or other allergic-type reactions after taking aspirin or other
                     NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been
                     reported in such patients [see Warnings and Precautions (<a href="#s15">5.7</a>, <a href="#s21">5.13</a>)]. </p>
<p>Zipsor is contraindicated for the treatment of perioperative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in
                     the setting of coronary artery bypass graft (CABG) surgery [see Warnings and
                     Precautions (<a href="#s9">5.1</a>)].</p>
<p>Zipsor contains gelatin and is contraindicated in patients with known
                     <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to bovine protein.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s8"></a><a name="section-5"></a><p></p>
<h1>5. WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Cardiovascular Thrombotic Events</h2>
<p class="First">Clinical trials of several COX-2 selective and nonselective
                           NSAIDs of up to three years duration have shown an increased risk of
                           serious cardiovascular (CV) thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and
                           <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. All NSAIDs, both COX-2 selective and
                           nonselective, may have a similar risk. Patients with known CV disease or
                           risk factors for CV disease may be at greater risk. To minimize the
                           potential risk for an adverse CV event in patients treated with an NSAID,
                           use the lowest effective dose for the shortest duration possible.
                           Physicians and patients should remain alert for the development of such
                           events, even in the absence of previous CV symptoms. Inform patients
                           about the signs and/or symptoms of serious CV events and the steps to
                           take if they occur. </p>
<p>Two large, controlled, clinical trials of a COX-2 selective NSAID
                           for the treatment of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the first 10-14 days following CABG surgery
                           found an increased incidence of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> [see
                           Contraindications (<a href="#s7">4</a>)]. </p>
<p>There is no consistent evidence that concurrent use of aspirin
                           mitigates the increased risk of serious CV thrombotic events associated
                           with NSAID use. The concurrent use of aspirin and an NSAID, such as
                           diclofenac, does increase the risk of serious GI events [see Warnings and
                           Precautions (<a href="#s10">5.2</a>)]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Gastrointestinal (GI) Effects – Risk of GI Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and
                        Perforation</h2>
<p class="First">NSAIDs, including diclofenac, can cause serious gastrointestinal
                           (GI) adverse events including, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of
                           the stomach, small intestine, or large intestine, which can be fatal.
                           These serious adverse events can occur at any time, with or without
                           warning symptoms, in patients treated with NSAIDs. Only one in five
                           patients, who develop a serious upper GI adverse event on NSAID therapy,
                           is symptomatic. Upper GI <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>, gross <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or perforation caused by
                           NSAIDs occur in approximately 1% of patients treated for 3-6 months, and
                           in about 2%-4% of patients treated for one year. These trends continue
                           with longer duration of use, increasing the likelihood of developing a
                           serious GI event at some time during the course of therapy. However, even
                           short-term NSAID therapy is not without risk. </p>
<p>Prescribe NSAIDs, including Zipsor, with extreme caution in
                           patients with a prior history of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> disease or gastrointestinal
                           <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Patients with a prior history of <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span> and/or GI
                           <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> who use NSAIDs have a greater than 10-fold increased risk for
                           developing a <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">GI bleed</span> compared to patients with neither of these risk
                           factors. Other factors that increase the risk for GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients
                           treated with NSAIDs include concomitant use of oral corticosteroids or
                           anticoagulants, longer duration of NSAID therapy, smoking, use of
                           alcohol, older age, and poor general health status. Most spontaneous
                           reports of fatal GI events are in elderly or debilitated patients, and
                           therefore special care should be taken in treating this population. </p>
<p>To minimize the potential risk for an adverse GI event in
                           patients treated with an NSAID, use the lowest effective dose for the
                           shortest possible duration. Patients and physicians should remain alert
                           for signs and symptoms of GI ulceration and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> during Zipsor
                           therapy and promptly initiate additional evaluation and treatment if a
                           serious GI adverse event is suspected. This should include
                           discontinuation of Zipsor until a serious GI adverse event is ruled out.
                           For high risk patients, alternative therapies that do not include NSAIDs
                           should be considered. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Hepatic Effects</h2>
<p class="First">Borderline elevations (less than 3 times the upper limit of the
                           normal [ULN] range) or greater elevations of transaminases occurred in
                           about 15% of diclofenac-treated patients in clinical trials of
                           indications other than <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">acute pain</span>. Of the markers of hepatic function,
                           ALT (SGPT) is recommended for the monitoring of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>. </p>
<p>In clinical trials of a diclofenac - misoprostol combination
                           product, meaningful elevations (i.e., more than 3 times the ULN) of AST
                           (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>) occurred in about 2% of approximately 5,700 patients at some time
                           during diclofenac treatment (ALT was not measured in all studies). </p>
<p>In an open-label, controlled trial of 3,700 patients treated for
                           2–6 months, patients were monitored first at 8 weeks and 1,200 patients
                           were monitored again at 24 weeks. Meaningful elevations of ALT and/or AST
                           occurred in about 4% of the 3,700 patients and included marked elevations
                           (&gt;8 times the ULN) in about 1% of the 3,700 patients. In this
                           open-label study, a higher incidence of borderline (less than 3 times the
                           ULN), moderate (3–8 times the ULN), and marked (&gt;8 times the ULN)
                           elevations of ALT or AST was observed in patients receiving diclofenac
                           when compared to other NSAIDs. Elevations in transaminases were seen more
                           frequently in patients with <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> than in those with rheumatoid
                           <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>. Almost all meaningful elevations in transaminases were
                           detected before patients became symptomatic. </p>
<p>Abnormal tests occurred during the first 2 months of therapy with
                           diclofenac in 42 of the 51 patients in all trials who developed marked
                           transaminase elevations. In postmarketing reports, cases of drug-induced
                           hepatotoxicity have been reported in the first month, and in some cases,
                           the first 2 months of NSAID therapy. </p>
<p>Postmarketing surveillance has reported cases of severe hepatic
                           reactions, including <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">liver necrosis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, fulminant <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> with
                           and without <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>. Some of these reported cases
                           resulted in fatalities or liver transplantation. </p>
<p>In a European retrospective population-based, case-controlled
                           study, 10 cases of diclofenac associated drug-induced <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> with
                           current use compared with non-use of diclofenac were associated with a
                           statistically significant 4-fold adjusted odds ratio of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>. In
                           this particular study, based on an overall number of 10 cases of liver
                           injury associated with diclofenac, the adjusted odds ratio increased
                           further with female gender, doses of 150 mg or more, and duration of use
                           for more then 90 days. </p>
<p>Physicians should measure transaminases (ALT and AST)
                           periodically in patients receiving long-term therapy with diclofenac,
                           because severe hepatotoxicity may develop without a prodrome of
                           distinguishing symptoms. The optimum times for making the first and
                           subsequent transaminase measurements are not known. Based on clinical
                           trial data and postmarketing experiences, transaminases should be
                           monitored within 4 to 8 weeks after initiating treatment with diclofenac.
                           However, severe hepatic reactions can occur at any time during treatment
                           with diclofenac. If abnormal liver tests persist or worsen, if clinical
                           signs and/or symptoms consistent with liver disease develop, or if
                           systemic manifestations occur (e.g., <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>,
                           <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, dark urine, etc.), discontinue Zipsor immediately. </p>
<p>To minimize the possibility that hepatic injury will become
                           severe between transaminase measurements, inform patients of the warning
                           signs and symptoms of hepatotoxicity (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>,
                           <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, right upper quadrant <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, and
                           "flu-like" symptoms), and the appropriate action patients should take if
                           these signs and symptoms appear. </p>
<p>To minimize the potential risk for an adverse liver-related event
                           in patients treated with Zipsor, use the lowest effective dose for the
                           shortest duration possible. Exercise caution when prescribing Zipsor with
                           concomitant drugs that are known to be potentially hepatotoxic (e.g.,
                           acetaminophen, certain antibiotics, antiepileptics). Caution patients to
                           avoid taking unprescribed acetaminophen while using Zipsor. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First">NSAIDs, including diclofenac, can lead to new onset or worsening
                           of preexisting <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, either of which may contribute to the
                           increased incidence of CV events. Use NSAIDs, including Zipsor, with
                           caution in patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Monitor blood pressure (BP)
                           closely during the initiation of NSAID treatment and throughout the
                           course of therapy. </p>
<p>Patients taking ACE inhibitors, thiazides or loop diuretics may
                           have impaired response to these therapies when taking NSAIDs.
                        </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> have been observed in some patients
                           taking NSAIDs. Use Zipsor with caution in patients with <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>
                           or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Renal Effects</h2>
<p class="First">Use caution when initiating treatment with Zipsor in patients
                           with considerable <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>. </p>
<p>Long-term administration of NSAIDs has resulted in renal
                           papillary <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> and other <span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">renal injury</span>. Renal toxicity has also been
                           seen in patients in whom renal prostaglandins have a compensatory role in
                           the maintenance of renal perfusion. In these patients, administration of
                           an NSAID may cause a dose-dependent reduction in prostaglandin formation
                           and, secondarily, in renal blood flow, which may precipitate overt renal
                           decompensation. Patients at greatest risk of this reaction are those with
                           <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, liver dysfunction, those taking
                           diuretics and ACE inhibitors, and the elderly. Discontinuation of NSAID
                           therapy is usually followed by recovery to the pretreatment state. </p>
<p>No information is available from controlled clinical studies
                           regarding the use of Zipsor in patients with advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>.
                           Therefore, treatment with Zipsor is not recommended in patients with
                           advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. If Zipsor therapy must be initiated, close
                           monitoring of the patient's renal function is advisable. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></h2>
<p class="First">As with other NSAIDs, <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> may occur in
                           patients without known prior exposure to Zipsor. Zipsor is
                           contraindicated in patients with the aspirin triad. This symptom complex
                           typically occurs in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> patients who experience <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> with or
                           without <span class="product-label-link" type="condition" conceptid="253788" conceptname="Nasal polyp">nasal polyps</span>, or who exhibit severe, potentially fatal
                           <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> after taking aspirin or other NSAIDs [see Contraindications
                              (<a href="#s7">4</a>)]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Adverse <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></h2>
<p class="First">NSAIDs, including diclofenac, can cause serious skin adverse
                           reactions such as <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span> (SJS),
                           and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN), which can be fatal. These serious
                           events may occur without warning. Patients should be informed about the
                           signs and symptoms of serious skin manifestations, and to discontinue
                           Zipsor at the first appearance of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or any other sign of
                           <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> [see Contraindications (<a href="#s7">4</a>)]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Pregnancy</h2>
<p class="First">Starting at 30 weeks gestation, Zipsor, as with other NSAIDs,
                           should be avoided by pregnant women as premature closure of the ductus
                           arteriosus in the fetus may occur. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Corticosteroid Treatment</h2>
<p class="First">Zipsor cannot be expected to substitute for corticosteroids or to
                           treat corticosteroid insufficiency. Abrupt discontinuation of
                           corticosteroids may lead to exacerbation of corticosteroid-responsive
                           illness. Patients on prolonged corticosteroid therapy should have their
                           therapy tapered slowly if a decision is made to discontinue
                           corticosteroids. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-5.11"></a><p></p>
<h2>5.11 Masking of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></h2>
<p class="First">The pharmacological activity of diclofenac in reducing
                           <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, and possibly <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, may diminish the utility of diagnostic
                           signs in detecting infectious complications of presumed noninfectious,
                           painful conditions. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-5.12"></a><p></p>
<h2>5.12 Hematological Effects</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> may occur in patients receiving NSAIDs. This may be due to
                           <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, occult or gross GI blood loss, or an incompletely
                           described effect upon erythropoiesis. In patients on long-term therapy
                           with NSAIDs, including diclofenac, check hemoglobin or hematocrit if they
                           exhibit any signs or symptoms of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> or blood loss. Zipsor is not
                           indicated for long-term treatment. </p>
<p>NSAIDs inhibit platelet aggregation and have been shown to
                           prolong <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> in some patients. Unlike aspirin, their effect on
                           platelet function is quantitatively less, of shorter duration, and
                           reversible. Carefully monitor patients treated with Zipsor who may be
                           adversely affected by alterations in platelet function, such as those
                           with <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulation disorders</span> or patients receiving anticoagulants.
                        </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-5.13"></a><p></p>
<h2>5.13 Use in Patients with Preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> may have aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. The use
                           of aspirin in patients with aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> has been associated
                           with severe <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> which can be fatal. Since cross reactivity,
                           including <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, between aspirin and other NSAIDs has been
                           reported in such aspirin-sensitive patients, Zipsor is contraindicated in
                           patients with this form of aspirin sensitivity and should be used with
                           caution in all patients with preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> [see Contraindications
                              (<a href="#s7">4</a>)]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-5.14"></a><p></p>
<h2>5.14 Monitoring</h2>
<p class="First">Because serious GI tract ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can occur
                           without warning symptoms, physicians should monitor for signs or symptoms
                           of GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. For patients on long-term treatment with NSAIDs,
                           periodically check a CBC and a chemistry profile. Discontinue Zipsor if
                           abnormal liver tests or renal tests persist or worsen. Zipsor is not
                           indicated for long-term treatment. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s23"></a><a name="section-6"></a><p></p>
<h1>6. ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are discussed elsewhere in the
                     labeling:</p>
<ul class="Disc">
<li>Cardiovascular thrombotic events [see <a href="#s1">Boxed
                        Warning</a> and Warnings and Precautions (<a href="#s9">5.1</a>)]</li>
<li>Gastrointestinal effects [see <a href="#s1">Boxed
                        Warning</a> and Warnings and Precautions (<a href="#s10">5.2</a>)]</li>
<li>Hepatic effects [see Warnings and Precautions (<a href="#s11">5.3</a>)]</li>
<li><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> [see Warnings and Precautions (<a href="#s12">5.4</a>)]</li>
<li><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> [see Warnings and Precautions
                           (<a href="#s13">5.5</a>)]</li>
<li>Renal effects [see Warnings and Precautions (<a href="#s14">5.6</a>)]</li>
<li><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> [see Warnings and Precautions (<a href="#s15">5.7</a>)]</li>
<li>Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> [see Warnings and Precautions (<a href="#s16">5.8</a>)]</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="s24"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Study Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying
                           conditions, adverse reaction rates observed in clinical trials of a drug
                           cannot be directly compared with the rates in clinical trials of another
                           drug and may not reflect the rates observed in practice. </p>
<p>The safety of Zipsor was evaluated in 965 subjects. In patients
                           treated with Zipsor 25 mg (N=345) or a higher dose, three or four times a
                           day, for 4 to 5 days, the most common adverse reactions (i.e., reported
                           in ≥ 1% of Zipsor treated patients) were as follows: gastrointestinal
                           experiences including <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>,
                           <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and
                           increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>. (see <a href="#t1">Table 1</a>) </p>
<a name="t1"></a><table width="800">
<caption><span>Table 1 Incidence of Treatment Emergent Adverse Reactions with
                              Incidence ≥ 1% of Zipsor Treated Patients in Multiple-Dose
                              Studies </span></caption>
<tfoot><tr class="First Last"><td align="left" colspan="5" valign="top"><p class="First Footnote">*There was greater use of
                                       concomitant opioid rescue medication in placebo treated
                                       patients than in Zipsor treated patients. </p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule" align="left" valign="top"><span class="Bold">MedDRA System Organ Class and
                                       Preferred <br>Term</span></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" colspan="2" valign="top">
<span class="Bold">Zipsor*</span><br><span class="Bold">25 mg </span><br><span class="Bold">n=345</span><br><span class="Bold">n (%)</span>
</td>
<td class="Botrule" align="center" valign="top">
<span class="Bold">Placebo*</span><br><br><span class="Bold">n=327</span><br><span class="Bold">n (%)</span>
</td>
</tr>
<tr>
<td align="left" valign="top">Any Adverse Events</td>
<td align="center" valign="top"></td>
<td align="center" colspan="2" valign="top">144 (41.7)</td>
<td align="center" valign="top">181 (55.4)</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td align="center" valign="top"></td>
<td align="center" colspan="2" valign="top">24 (7.0)</td>
<td align="center" valign="top">11 (3.4)</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td align="center" valign="top"></td>
<td align="center" colspan="2" valign="top">11 (3.2)</td>
<td align="center" valign="top">9 (2.8)</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center" valign="top"></td>
<td align="center" colspan="2" valign="top">8 (2.3)</td>
<td align="center" valign="top">9 (2.8)</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td align="center" valign="top"></td>
<td align="center" colspan="2" valign="top">4 (1.2)</td>
<td align="center" valign="top">8 (2.4)</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center" valign="top"></td>
<td align="center" colspan="2" valign="top">57 (16.5)</td>
<td align="center" valign="top">66 (20.2)</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center" valign="top"></td>
<td align="center" colspan="2" valign="top">20 (5.8)</td>
<td align="center" valign="top">26 (8.0)</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center" valign="top"></td>
<td align="center" colspan="2" valign="top">12 (3.5)</td>
<td align="center" valign="top">17 (5.2)</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center" valign="top"></td>
<td align="center" colspan="2" valign="top">43 (12.5)</td>
<td align="center" valign="top">56 (17.1)</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="center" valign="top"></td>
<td align="center" colspan="2" valign="top">9 (2.6)</td>
<td align="center" valign="top">6 (1.8)</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td align="center" valign="top"></td>
<td align="center" colspan="2" valign="top">5 (1.4)</td>
<td align="center" valign="top">6 (1.8)</td>
</tr>
<tr class="Last">
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span> Increase</td>
<td align="center" valign="top"></td>
<td align="center" colspan="2" valign="top">4 (1.2)</td>
<td align="center" valign="top">2 (0.6)</td>
</tr>
</tbody>
</table>
<p>In patients taking other NSAIDs, the most frequently reported
                           adverse experiences occurring in approximately 1%-10% of patients are:</p>
<p>Gastrointestinal experiences including: <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>,
                           <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, gross
                           <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>/perforation, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, GI <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> (gastric/duodenal) and
                           <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p>Abnormal renal function, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, elevated liver
                           enzymes, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, increased <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span>, and
                           <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>.</p>
<p>Additional adverse experiences reported in patients taking other
                           NSAIDs occasionally include:</p>
<p><span class="Bold Italics">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>,
                           <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> <br><span class="Bold Italics">Cardiovascular
                              System:</span> <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>,
                           <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> <br><span class="Bold Italics">Digestive
                           System:</span> <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, gastric/<span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcers</span>,
                           <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>,
                           <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> <br><span class="Bold Italics">Hemic and Lymphatic
                              System:</span> <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>,
                           <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> <br><span class="Bold Italics">Metabolic and Nutritional:</span> weight
                           changes <br><span class="Bold Italics">Nervous System:</span>
                           <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, dream abnormalities,
                           <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>,
                           <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span> <br><span class="Bold Italics">Respiratory
                              System:</span> <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> <br><span class="Bold Italics">Skin and Appendages:</span> <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>,
                           <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating increased</span> <br><span class="Bold Italics">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>
                              <br><span class="Bold Italics">Urogenital System:</span>
                           <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>/<span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>,
                           <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span></p>
<p>Other adverse reactions in patients taking other NSAIDs, which
                           occur rarely are: <br><span class="Bold Italics">Body as a
                           Whole:</span> <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>, appetite changes, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>
                              <br><span class="Bold Italics">Cardiovascular
                           System:</span> <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>,
                           <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span> <br><span class="Bold Italics">Digestive
                              System:</span> <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>
                              <br><span class="Bold Italics">Hemic and Lymphatic
                           System:</span> <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>,
                           <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span> <br><span class="Bold Italics">Metabolic and Nutritional:</span> <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> <br><span class="Bold Italics">Nervous System:</span> <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>,
                           <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> <br><span class="Bold Italics">Respiratory System:</span> <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>
                              <br><span class="Bold Italics">Skin and Appendages:</span>
                           <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, exfoliative
                           <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> <br><span class="Bold Italics">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>,
                           hearing impairment</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s25"></a><a name="section-7"></a><p></p>
<h1>7. DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s26"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Aspirin</h2>
<p class="First">When administered with aspirin, diclofenac's protein binding is
                           reduced. The clinical significance of this interaction is not known;
                           however, as with other NSAIDs, concomitant administration of Zipsor and
                           aspirin is not generally recommended because of the potential of
                           increased adverse effects. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s27"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Anticoagulants</h2>
<p class="First">The effects of anticoagulants such as of warfarin and NSAIDs on
                           GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> are synergistic, such that users of both drugs together have
                           a risk of serious GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> higher than that with use of either drug
                           alone.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s28"></a><a name="section-7.3"></a><p></p>
<h2>7.3 ACE-inhibitors</h2>
<p class="First">NSAIDs may diminish the antihypertensive effect of angiotensin
                           converting enzyme (ACE) inhibitors. This interaction should be given
                           consideration in patients taking Zipsor concomitantly with
                           ACE-inhibitors.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s29"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Diuretics</h2>
<p class="First">Clinical studies, as well as post-marketing observations, have
                           shown that NSAIDs can reduce the natriuretic effect of furosemide and
                           thiazides in some patients. This response has been attributed to
                           inhibition of renal prostaglandin synthesis. During concomitant therapy
                           of Zipsor and diuretics, observe patients closely for signs of renal
                           failure [see Warnings and Precautions (<a href="#s14">5.6</a>)], as well as to assure diuretic efficacy. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s30"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Lithium</h2>
<p class="First">NSAIDs have produced an elevation of plasma lithium levels and a
                           reduction in renal lithium clearance. The mean minimum lithium
                           concentration increased 15% and the renal clearance was decreased by
                           approximately 20%. These effects have been attributed to inhibition of
                           renal prostaglandin synthesis by the NSAID. Thus, when Zipsor and lithium
                           are administered concurrently, observe patients carefully for signs of
                           <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s31"></a><a name="section-7.6"></a><p></p>
<h2>7.6 Methotrexate</h2>
<p class="First">NSAIDs have been reported to competitively inhibit methotrexate
                           accumulation in rabbit kidney slices. This indicates that NSAIDs may
                           enhance the toxicity of methotrexate. Use caution when Zipsor is
                           administered concomitantly with methotrexate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s32"></a><a name="section-7.7"></a><p></p>
<h2>7.7 Cyclosporine</h2>
<p class="First">Diclofenac, like other NSAIDs, may affect renal prostaglandins
                           and increase the toxicity of certain drugs. Therefore, concomitant
                           therapy with Zipsor may increase cyclosporine's <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>. Use
                           caution when Zipsor is administered concomitantly with cyclosporine.
                        </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s33"></a><a name="section-7.8"></a><p></p>
<h2>7.8 Inhibitors or Substrates of Cytochrome P450 2C9 Other Considerations</h2>
<p class="First">Diclofenac is metabolized predominantly by cytochrome P450 2C9.
                           Co-administration of diclofenac with another drug medication known to be
                           metabolized by or that which inhibits Cytochrome P450 2C9 may
                           unpredictably affect the pharmacokinetics of diclofenac or the
                           co-administered drug medication. Caution should be used to evaluate each
                           patient's medical history when consideration is given to prescribing
                           Zipsor [see Clinical Pharmacology (<a href="#s45">12.3</a>)]. </p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s34"></a><a name="section-8"></a><p></p>
<h1>8. USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s35"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="s36"></a><a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Italics">Teratogenic Effects:</span>
                                 Pregnancy Category C prior to 30 weeks gestation; Category D
                                 starting 30 weeks gestation.</p>
<p>Starting at 30 weeks gestation, Zipsor, and other NSAIDs,
                                 should be avoided by pregnant women as premature closure of the
                                 ductus arteriosus in the fetus may occur. Zipsor can cause fetal
                                 harm when administered to a pregnant woman starting at 30 weeks
                                 gestation. If this drug is used during this time period in
                                 pregnancy, the patient should be apprised of the potential hazard
                                 to a fetus. There are no adequate and well-controlled studies in
                                 pregnant women. Prior to 30 weeks gestation, Zipsor should be used
                                 during pregnancy only if the potential benefit justifies the
                                 potential risk to the fetus. </p>
<p>Reproductive studies have been performed in mice given
                                 diclofenac sodium (up to 20 mg/kg/day or 60 mg/m<span class="Sup">2</span>/day)
                                 and in rats and rabbits given diclofenac sodium (up to 10 mg/kg/day
                                 or 60 mg/m<span class="Sup">2</span>/day for rats, and 80 mg/m<span class="Sup">2</span>/day
                                 for rabbits, 1-fold and 2-fold an adult human daily dose of 100
                                 mg/day, respectively), and have revealed no evidence of
                                 <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> despite the induction of maternal toxicity and fetal
                                 toxicity. In rats, maternally toxic doses were associated with
                                 dystocia, prolonged gestation, reduced fetal weights and growth,
                                 and reduced fetal survival. Diclofenac has been shown to cross the
                                 placental barrier in mice, rats, and humans. </p>
<p>Literature studies have shown that diclofenac has been
                                 shown to exert direct teratogenic effects on rat embryos in vitro
                                 at concentrations of 7.5 and 15 μg/mL, and diclofenac exposure to
                                 pregnant rats (1 mg/kg, IP) can lead to prolonged gestation as well
                                 as liver toxicity and neuronal loss in offspring. </p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="s37"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">The effects of Zipsor on labor and delivery in pregnant women are
                           unknown. In rat studies maternal exposure to NSAIDs, as with other drugs
                           known to inhibit prostaglandin synthesis, increased incidence of
                           dystocia, delayed parturition, and decreased pup survival. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s38"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk;
                           however, there is a case report in the literature indicating that
                           diclofenac can be detected at low levels in breast milk. Because many
                           drugs are excreted in human milk and because of the potential for serious
                           adverse reactions in nursing infants from Zipsor, a decision should be
                           made whether to discontinue nursing or to discontinue the drug, taking
                           into account the importance of the drug to the mother. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s39"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of Zipsor in pediatric patients has
                           not been established. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s40"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of Zipsor did not include sufficient numbers of
                           subjects aged 65 and over to determine whether they respond differently
                           from younger subjects. Other reported clinical experience has not
                           identified differences in responses between the elderly and younger
                           patients. In general, dose selection for an elderly patient should be
                           cautious, usually starting at the low end of the dosing range, reflecting
                           the greater frequency of decreased hepatic, renal, or cardiac function,
                           and concomitant disease or other drug therapy. </p>
<p>Diclofenac is known to be substantially excreted by the kidney,
                           and the risk of adverse reactions to this drug may be greater in patients
                           with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to
                           have decreased renal function, care should be taken in dose selection,
                           and it may be useful to monitor renal function. Older age increases the
                           risk for GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Most spontaneous reports of fatal GI events are in
                           elderly or debilitated patients, and therefore special care should be
                           taken in treating this population [see Gastrointestinal (GI) Effects –
                           Risk of GI Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation (<a href="#s10">5.2</a>)]. </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s41"></a><a name="section-9"></a><p></p>
<h1>10. OVERDOSAGE</h1>
<p class="First">Symptoms following acute NSAID <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> include <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>,
                     <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">epigastric pain</span>, which are generally reversible with
                     supportive care. <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal bleeding</span> can occur. <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>, acute renal
                     failure, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> may occur. </p>
<p>Patients should be managed by symptomatic and supportive care following
                     an NSAID <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. There are no specific antidotes. Activated charcoal (60 to
                     100 g in adults, 1 to 2 g/kg in children) and/or osmotic cathartic may be
                     indicated in patients seen within 4 hours of ingestion with symptoms or
                     following a large <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> (5 to 10 times the usual dose). Forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>,
                     alkalinization of urine, hemodialysis, or hemoperfusion may not be useful due
                     to high protein binding. </p>
<p>For additional information about <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> treatment, call the poison
                     control center at 1-800-222-1222. </p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s42"></a><a name="section-10"></a><p></p>
<h1>11. DESCRIPTION</h1>
<p class="First">Zipsor (diclofenac potassium) Liquid Filled Capsule is a benzeneacetic
                     acid derivative NSAID. Zipsor is available as liquid-filled capsules of 25 mg
                     for oral administration. The chemical name is 2-[(2,6- dichlorophenyl) amino]
                     benzeneacetic acid monopotassium salt. The molecular weight is 334.24. Its
                     molecular formula is C<span class="Sub">14</span>H<span class="Sub">10</span>Cl<span class="Sub">2</span>NKO<span class="Sub">2</span>,
                     and it has the following structural formula. </p>
<div class="Figure">
<a name="f01"></a><img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c982eca0-fc41-11e1-a9c8-0002a5d5c51b&amp;name=zip00-0001-01.jpg">
</div>
<p>The inactive ingredients in Zipsor include ProSorb<span class="Sup">®</span> (a
                     proprietary combination of polyethylene glycol 400, glycerin, sorbitol,
                     povidone, polysorbate 80, and hydrochloric acid), isopropyl alcohol, and
                     mineral oil. The capsule shells contain gelatin, sorbitol, isopropyl alcohol,
                     glycerin, and mineral oil. The imprinting on the gelatin capsules is black
                     edible ink. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s43"></a><a name="section-11"></a><p></p>
<h1>12. CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s44"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Zipsor is an NSAID that exhibits anti-inflammatory, analgesic,
                           and antipyretic activities in animal models. The mechanism of action of
                           Zipsor, like that of other NSAIDs, is not completely understood but may
                           involve inhibition of the cyclooxygenase (COX-1 and COX-2) pathways.
                           Diclofenac's mechanism may also be related to prostaglandin synthetase
                           inhibition. The analgesic mechanism of action needs further elucidation.
                        </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s45"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The pharmacokinetics of Zipsor was assessed in 24 healthy, normal
                           volunteers who received 25 mg Zipsor under fasting conditions. The mean
                           pharmacokinetic parameters for Zipsor are shown in <a href="#t2">Table 2</a>.</p>
<a name="t2"></a><table width="100%">
<caption><span>Table 2 Mean Pharmacokinetics of Zipsor</span></caption>
<col align="left" width="32.600%">
<col align="left" width="25.900%">
<col align="left" width="41.500%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="center" valign="top"><span class="Bold">PK Parameter</span></td>
<td class="Botrule Toprule" align="center" valign="top"><span class="Bold">Number of Subjects</span></td>
<td class="Botrule Toprule" align="center" valign="top">
<span class="Bold">Mean</span> ± <span class="Bold">Standard Deviation</span>
</td>
</tr>
<tr>
<td align="center" valign="top">T<span class="Sub">max</span> (hr)</td>
<td align="center" valign="top">24</td>
<td align="center" valign="top">0.47 ± 0.17</td>
</tr>
<tr>
<td align="center" valign="top">Terminal Half-life (hr)</td>
<td align="center" valign="top">24</td>
<td align="center" valign="top">1.07 ± 0.29</td>
</tr>
<tr>
<td align="center" valign="top">C<span class="Sub">max</span> (ng/mL)</td>
<td align="center" valign="top">24</td>
<td align="center" valign="top">1087 ± 419</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="top">AUC(0-∞) (ng·h/mL)</td>
<td class="Botrule" align="center" valign="top">24</td>
<td class="Botrule" align="center" valign="top">597 ±
                                    151</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="s46"></a><a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Italics">Absorption</span></p>
<p>Diclofenac is 100% absorbed after oral administration
                                 compared to IV administration as measured by urine recovery.
                                 However, due to first-pass metabolism, only about 50% of the
                                 absorbed dose is systemically available. After repeated oral
                                 administration, no accumulation of diclofenac in plasma occurred. </p>
<p>The extent of diclofenac absorption is not significantly
                                 affected when Zipsor is taken with food. However, the rate of
                                 absorption is reduced by food, as indicated by a two-fold increase
                                 of T<span class="Sub">max</span> and a 47% decrease in C<span class="Sub">max</span>.
                              </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s47"></a><a name="section-11.2.2"></a><p></p>
<p class="First"><span class="Italics">Distribution</span></p>
<p>The apparent volume of distribution (V/F) of diclofenac
                                 potassium is 1.3 L/kg. </p>
<p>Diclofenac is more than 99% bound to human serum proteins,
                                 primarily to albumin. Serum protein binding is constant over the
                                 concentration range (0.15-105 μg/mL) achieved with recommended
                                 doses.</p>
<p>Diclofenac diffuses into and out of the synovial fluid.
                                 Diffusion into the joint occurs when plasma levels are higher than
                                 those in the synovial fluid, after which the process reverses and
                                 synovial fluid levels are higher than plasma levels. It is not
                                 known whether diffusion into the joint plays a role in the
                                 effectiveness of diclofenac. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s48"></a><a name="section-11.2.3"></a><p></p>
<p class="First"><span class="Italics">Metabolism</span></p>
<p>Five diclofenac metabolites have been identified in human
                                 plasma and urine. The metabolites include 4'-hydroxy-, 5-hydroxy-,
                                 3'-hydroxy-, 4',5-dihydroxy- and 3'-hydroxy-4'-methoxy diclofenac.
                                 The major diclofenac metabolite, 4'-hydroxy-diclofenac, has very
                                 weak pharmacologic activity. The formation of 4'-hydroxy diclofenac
                                 is primarily mediated by CPY2C9. Both diclofenac and its oxidative
                                 metabolites undergo glucuronidation or sulfation followed by
                                 biliary excretion. Acylglucuronidation mediated by UGT2B7 and
                                 oxidation mediated by CPY2C8 may also play a role in diclofenac
                                 metabolism. CYP3A4 is responsible for the formation of minor
                                 metabolites, 5-hydroxy and 3'-hydroxy- diclofenac. In patients with
                                 renal dysfunction, peak concentrations of metabolites
                                 4'-hydroxy-and 5-hydroxy-diclofenac were approximately 50% and 4%
                                 of the parent compound after single oral dosing compared to 27% and
                                 1% in normal healthy subjects. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s49"></a><a name="section-11.2.4"></a><p></p>
<p class="First"><span class="Italics">Excretion</span></p>
<p>Diclofenac is eliminated through metabolism and subsequent
                                 urinary and biliary excretion of the glucuronide and the sulfate
                                 conjugates of the metabolites. Little or no free unchanged
                                 diclofenac is excreted in the urine. Approximately 65% of the dose
                                 is excreted in the urine, and approximately 35% in the bile as
                                 conjugates of unchanged diclofenac plus metabolites. Because renal
                                 elimination is not a significant pathway of elimination for
                                 unchanged diclofenac, dosing adjustment in patients with mild to
                                 moderate renal dysfunction is not necessary. The terminal half-life
                                 of unchanged diclofenac is approximately 1 hour. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s50"></a><a name="section-11.2.5"></a><p></p>
<p class="First"><span class="Italics">Special Populations</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s51"></a><a name="section-11.2.6"></a><p></p>
<p class="First"><span class="Italics">Pediatric:</span> The
                                 pharmacokinetics of Zipsor has not been investigated in pediatric
                                 patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s52"></a><a name="section-11.2.7"></a><p></p>
<p class="First"><span class="Italics">Race:</span> Pharmacokinetic
                                 differences due to race have not been studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s53"></a><a name="section-11.2.8"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span> Hepatic
                                 metabolism accounts for almost 100% of diclofenac elimination, so
                                 patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> may require reduced doses of Zipsor
                                 compared to patients with normal hepatic function. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s54"></a><a name="section-11.2.9"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> Diclofenac
                                 pharmacokinetics has been investigated in subjects with renal
                                 insufficiency. In patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (inulin clearance
                                 60-90, 30-60, and &lt;30 mL/min; N=6 in each group), AUC values
                                 and elimination rate were comparable to those in healthy subjects.
                              </p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s55"></a><a name="section-12"></a><p></p>
<h1>13. NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s56"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenesis: Long-term carcinogenicity studies in rats given
                           diclofenac sodium up to 2 mg/kg/day (or 12 mg/m<span class="Sup">2</span>/day, 0.2-fold
                           an adult human daily dose of 100 mg/day) have revealed no significant
                           increase in tumor incidence. A 2-year carcinogenicity study conducted in
                           mice employing diclofenac sodium at doses up to 0.3 mg/kg/day (0.9
                              mg/m<span class="Sup">2</span>/day, 0.014-fold an adult human daily dose of 100
                           mg/day) in males and 1 mg/kg/day (3 mg/m<span class="Sup">2</span>/day, 0.04-fold an
                           adult human daily dose of 100 mg/day) in females did not reveal any
                           oncogenic potential. </p>
<p>Mutagenesis: Diclofenac sodium did not show mutagenic activity in
                           in vitro point mutation assays in mammalian (mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>) and
                           microbial (yeast, Ames) test systems and was nonmutagenic in several
                           mammalian in vitro and in vivo tests, including dominant lethal and male
                           germinal epithelial chromosomal aberration studies in Chinese hamsters. </p>
<p>Impairment of Fertility: Diclofenac sodium administered to male
                           and female rats at 4 mg/kg/day (24 mg/m<span class="Sup">2</span>/day, 0.4-fold an
                           adult human daily dose of 100 mg/day) did not affect
                        fertility.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s57"></a><a name="section-13"></a><p></p>
<h1>14. CLINICAL STUDIES</h1>
<p class="First">The efficacy of Zipsor was demonstrated in two multicenter, randomized,
                     double-blind, placebo- controlled, parallel arm, multiple-dose clinical trials
                     comparing Zipsor 25 mg and placebo in patients with <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> following bunionectomy
                     with osteotomy. Once patients met the criteria for randomization (<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>
                     intensity ≥4 on a 0-10 numerical <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> rating scale) they received their initial
                     dose of study medication followed by a remedication dose when requested by the
                     patient, and were then dosed every six hours over four days. <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> intensity was
                     recorded at 3 and 6 hours postdose during the fixed dosing period. In Study 1,
                     mean baseline <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity scores were 6.9 in the Zipsor group (range: 4 –
                     10) and 7.3 in the placebo group (range: 4 – 10). In both studies, patients
                     treated with Zipsor had a lower mean <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity score over the 48-hour
                     inpatient period following the first remedication dose (see <a href="#f02">Figure 1</a>). The median time to onset of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief
                     was less than one hour for Zipsor 25 mg across the clinical trials. </p>
<p>The results were similar in Study 2.</p>
<div class="Figure">
<a name="f02"></a><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c982eca0-fc41-11e1-a9c8-0002a5d5c51b&amp;name=zip00-0001-02.jpg"><p class="MultiMediaCaption">Figure 1 Mean <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Intensity Scores at the Midpoint and End of Each
                        Dose Interval in Postbunionectomy <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Study 1</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s58"></a><a name="section-14"></a><p></p>
<h1>16. HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Zipsor 25 mg is supplied as translucent, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow, liquid-filled
                     capsules printed with “X592? in black ink.
                     <br>Bottles of 100 Capsules NDC# 13913-008-11.
                     <br>Bottles of 120 Capsules NDC# 13913-008-12.</p>
<p>Store at 25°C (77°F); excursions permitted to
                     15°C-30°C (59°F-86°F). [See USP Controlled
                     Room Temperature]</p>
<p>Protect from moisture.</p>
<p>Dispense in tight container (USP).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s59"></a><a name="section-15"></a><p></p>
<h1>17. PATIENT COUNSELING INFORMATION</h1>
<p class="First">Inform patients of the availability of a Medication Guide for NSAIDs
                     that accompanies each prescription dispensed, and instruct them to read the
                     NSAID Medication Guide prior to using Zipsor [see <a href="#s67">Medication Guide</a>].</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s60"></a><a name="section-15.1"></a><p></p>
<h2>17.1 Cardiovascular Effects</h2>
<p class="First">NSAIDs, including diclofenac, may cause serious CV events, such
                           as MI or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which may result in hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.
                           Although serious CV events can occur without warning symptoms, advise
                           patients to be alert for the signs and symptoms of <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, shortness
                           of breath, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, slurring of speech, and to ask for medical advice
                           when observing any indicative sign or symptoms. Inform patients of the
                           importance of this follow-up [see Warnings and Precautions (<a href="#s9">5.1</a>)]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s61"></a><a name="section-15.2"></a><p></p>
<h2>17.2 Gastrointestinal Effects</h2>
<p class="First">NSAIDs, including diclofenac, can cause GI <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> and,
                           rarely, more serious GI side effects, such as <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, which
                           may result in hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious GI tract
                           ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can occur without warning symptoms, advise
                           patients to be alert for the signs and symptoms of ulcerations and
                           <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and to ask for medical advice when observing any indicative
                           sign or symptoms including <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">epigastric pain</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, and
                           <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>. Inform patients of the importance of this follow-up [see
                           Warnings and Precautions (<a href="#s10">5.2</a>)].
                        </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s62"></a><a name="section-15.3"></a><p></p>
<h2>17.3 Hepatotoxicity</h2>
<p class="First">Inform patients of the warning signs and symptoms of
                           hepatotoxicity (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>,
                           right upper quadrant <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, and “flu-like? symptoms). If these
                           occur, instruct patients to stop therapy with Zipsor and seek immediate
                           medical therapy [see Warnings and Precautions (<a href="#s11">5.3</a>)]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s63"></a><a name="section-15.4"></a><p></p>
<h2>17.4 Adverse <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></h2>
<p class="First">NSAIDs can cause serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> such as exfoliative
                           <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span> (SJS), and toxic epidermal
                           necrolysis (TEN), which may result in hospitalizations and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.
                           Although serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> may occur without warning, advise
                           patients to be alert for the signs and symptoms of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> and
                           <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, or other signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> such as <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, and
                           to ask for medical advice when observing any indicative signs or
                           symptoms. Advise patients to stop Zipsor immediately if they develop any
                           type of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and contact their physicians as soon as possible [see
                           Warnings and Precautions (<a href="#s16">5.8</a>)].
                        </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s64"></a><a name="section-15.5"></a><p></p>
<h2>17.5 <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></h2>
<p class="First">Advise patients to promptly report to their physicians signs or
                           symptoms of unexplained <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> during treatment with Zipsor
                           [see Warnings and Precautions (<a href="#s13">5.5</a>)].
                        </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s65"></a><a name="section-15.6"></a><p></p>
<h2>17.6 <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></h2>
<p class="First">Inform patients of the signs of an <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> (e.g.,
                           <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face or throat). Instruct patients
                           to seek immediate emergency help if these occur [see Warnings and
                           Precautions (<a href="#s15">5.7</a>)]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s66"></a><a name="section-15.7"></a><p></p>
<h2>17.7 Effects During Pregnancy</h2>
<p class="First">Starting at 30 weeks gestation, Zipsor and other NSAIDs, should
                           be avoided by pregnant women as premature closure of the ductus
                           arteriosus in the fetus may occur [see Use in Specific Populations
                              (<a href="#s35">8.1</a>)]. </p>
<p>US Patents: 6,365,180; 7,662,858; 7,884,095; 7,939,518; 8,110,606; 6,287,594; 8,623,920</p>
<p><span class="Bold">Marketed by:</span><br><span>Depomed, Inc.<br> Newark, CA 94560, USA</span></p>
<p> </p>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="s67"></a><a name="section-16"></a><p></p>
<p class="First">Medication Guide for Non-Steroidal Anti-Inflammatory Drugs
                     (NSAIDs)<br>(See the end of this Medication Guide for a list of prescription
                     NSAID medicines.) </p>
<p><span class="Bold">What is the most important information I should know
                        about medicines called Non-Steroidal Anti-Inflammatory Drugs
                     (NSAIDs)?</span></p>
<p><span class="Bold">NSAID medicines may increase the chance of a heart
                        attack or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></span>. This chance increases: </p>
<ul class="Disc">
<li>with longer use of NSAID medicines </li>
<li>in people who have heart disease </li>
</ul>
<p><span class="Bold">NSAID medicines should never be used right before or
                        after a heart surgery called a “coronary artery bypass graft
                     (CABG)."</span></p>
<p><span class="Bold">NSAID medicines can cause <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in the
                        stomach and intestines at any time during treatment. <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">Ulcers</span> and
                     <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>:</span></p>
<ul class="Disc">
<li>can happen without warning symptoms</li>
<li>may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></li>
</ul>
<p>The chance of a person getting an <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> increases with: </p>
<ul class="Disc">
<li>taking medicines called “corticosteroids? and “anticoagulants?</li>
<li>longer use</li>
<li>smoking</li>
<li>drinking alcohol</li>
<li>older age</li>
<li>having poor health</li>
</ul>
<p><span class="Bold">NSAID medicines should only be used:</span></p>
<ul class="Disc">
<li>exactly as prescribed</li>
<li>at the lowest dose possible for your treatment</li>
<li>for the shortest time needed</li>
</ul>
<p><span class="Bold">What are Non-Steroidal Anti-Inflammatory Drugs
                        (NSAIDs)?</span></p>
<p>NSAID medicines are used to treat <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and heat
                     (<span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>) from medical conditions such as: </p>
<ul class="Disc">
<li>different types of <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span></li>
<li><span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">menstrual cramps</span> and other types of short-term <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
</ul>
<p><span class="Bold">Who should not take a Non-Steroidal Anti-Inflammatory
                        Drug (NSAID)?</span></p>
<p>Do not take an NSAID medicine:</p>
<ul class="Disc">
<li>if you had an <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attack, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, or other <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> with
                        aspirin or any other NSAID medicine</li>
<li>for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> right before or after heart bypass surgery</li>
</ul>
<p><span class="Bold">Tell your healthcare provider:</span></p>
<ul class="Disc">
<li>about all of your medical conditions.</li>
<li>about all of the medicines you take. NSAIDs and some other medicines can
                        interact with each other and cause serious side effects. <span class="Bold">Keep a list of your medicines to show to your healthcare
                           provider and pharmacist.</span>
</li>
<li>if you are pregnant, NSAID medicines should not be used past 30 weeks of
                        pregnancy.</li>
<li>if you are breastfeeding, talk to your doctor.</li>
</ul>
<p><span class="Bold">What are the possible side effects of Non-Steroidal
                        Anti-Inflammatory Drugs (NSAIDs)?</span></p>
<table width="100%">
<col align="left" width="58.150%">
<col align="left" width="41.850%">
<tbody class="Headless"><tr class="First Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Serious side effects include:</span><br><ul class="Disc">
<li> <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span></li>
<li> <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></li>
<li> high blood pressure</li>
<li> <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> from body <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> (<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>)</li>
<li> kidney problems including <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span></li>
<li> <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in the stomach and intestine</li>
<li> low red blood cells (<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>)</li>
<li> life-threatening <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span></li>
<li> life-threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span></li>
<li> liver problems including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span></li>
<li> <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attacks in people who have <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span></li>
</ul>
</td>
<td class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Other side effects include:</span><br><ul class="Disc">
<li> <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li> <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></li>
<li> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li> gas</li>
<li> <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span></li>
<li> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li> <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
</ul>
</td>
</tr></tbody>
</table>
<p><span class="Bold">Get emergency help right away if you have any of the
                        following symptoms:</span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or trouble breathing</li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in one part or side of your body</li>
<li><span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face or throat</li>
</ul>
<p><span class="Bold">Stop your NSAID medicine and call your healthcare
                        provider right away if you have any of the following symptoms:</span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li>more tired or weaker than usual</li>
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></li>
<li>your skin or eyes look yellow</li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li>flu-like symptoms</li>
<li>vomit blood</li>
<li>there is blood in your bowel movement or it is black and sticky like tar</li>
<li>unusual <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span></li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the arms and legs, hands and feet</li>
</ul>
<p>These are not all the side effects with NSAID medicines. Talk to your
                     healthcare provider or pharmacist for more information about NSAID medicines.
                     Call your doctor for medical advice about side effects. You may report side
                     effects to FDA at 1-800-FDA-1088 or Depomed, Inc. at 1-866-458-6389. </p>
<p><span class="Bold">Other information about Non-Steroidal
                        Anti-Inflammatory Drugs (NSAIDs)</span></p>
<ul class="Disc">
<li>Aspirin is an NSAID medicine but it does not increase the chance of a
                        <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>. Aspirin can cause <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in the brain, stomach, and
                        intestines. Aspirin can also cause <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in the stomach and intestines.</li>
<li>Some of these NSAID medicines are sold in lower doses without a
                        prescription (over-the-counter). Talk to your healthcare provider before
                        using over –the –counter NSAIDs for more than 10 days.</li>
</ul>
<a name="t300"></a><table width="100%">
<caption><span>NSAID medicines that need a prescription </span></caption>
<col align="left" width="30.000%">
<col align="left" width="70.000%">
<tfoot><tr class="First Last"><td align="left" colspan="2" valign="top"><p class="First Footnote">*Vicoprofen contains the same dose of
                                 ibuprofen as over-the-counter (OTC) NSAIDs, and is usually used for
                                 less than 10 days to treat <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. The OTC NSAID label warns that
                                 long term continuous use may increase the risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or
                                 <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>. </p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Generic Name</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Trade Name</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Celecoxib</td>
<td class="Botrule Rrule" align="left" valign="top">Celebrex</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Diclofenac</td>
<td class="Botrule Rrule" align="left" valign="top">Cataflam,
                              Voltaren, Arthrotec (combined with misoprostol), Flector, Zipsor</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Diflunisal</td>
<td class="Botrule Rrule" align="left" valign="top">Dolobid</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Etodolac</td>
<td class="Botrule Rrule" align="left" valign="top">Lodine, Lodine
                           XL</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Fenoprofen</td>
<td class="Botrule Rrule" align="left" valign="top">Nalfon, Nalfon
                              200</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Flurbiprofen</td>
<td class="Botrule Rrule" align="left" valign="top">Ansaid</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Ibuprofen</td>
<td class="Botrule Rrule" align="left" valign="top">Motrin, 
                              Tab-Profen, *Vicoprofen (combined with hydrocodone), Combunox
                              (combined with oxycodone)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Indomethacin</td>
<td class="Botrule Rrule" align="left" valign="top">Indocin, Indocin
                              SR, Indo-Lemmon, Indomethagan</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Ketoprofen</td>
<td class="Botrule Rrule" align="left" valign="top">Oruvail</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Ketorolac</td>
<td class="Botrule Rrule" align="left" valign="top">Toradol</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Mefenamic 
                              Acid</td>
<td class="Botrule Rrule" align="left" valign="top">Ponstel</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Meloxicam</td>
<td class="Botrule Rrule" align="left" valign="top">Mobic</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Nabumetone</td>
<td class="Botrule Rrule" align="left" valign="top">Relafen</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Naproxen</td>
<td class="Botrule Rrule" align="left" valign="top">Naprosyn,
                              Anaprox, Anaprox DS, EC-Naprosyn, Naprelan, Naprapac (copackaged with
                              lansoprazole)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Oxaprozin</td>
<td class="Botrule Rrule" align="left" valign="top">Daypro</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Piroxicam</td>
<td class="Botrule Rrule" align="left" valign="top">Feldene</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Sulindac</td>
<td class="Botrule Rrule" align="left" valign="top">Clinoril</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Tolmetin</td>
<td class="Botrule Rrule" align="left" valign="top">Tolectin,
                              Tolectin DS, Tolectin 600</td>
</tr>
</tbody>
</table>
<p>This Medication Guide has been approved by the U.S. Food and Drug
                     Administration.</p>
<p>© 2015 Depomed, Inc.<br>ZIP-001-C.4 Rev. MAR 2015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s69"></a><a name="section-17"></a><p></p>
<h1>Principal Display Panel - 25 mg - 100-count Bottle Label</h1>
<p class="First">NDC 13913-008-11</p>
<p>100 Liquid Filled Capsules</p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">Zipsor<span class="Sup">®</span></span><br><span class="Italics">(diclofenac potassium)</span></p>
<p>Liquid Filled Capsules</p>
<p><span class="Bold">25 mg</span></p>
<p>Marketed by: Depomed<span class="Sup">®</span></p>
<div class="Figure">
<a name="f04"></a><img alt="25 mg 120-count Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c982eca0-fc41-11e1-a9c8-0002a5d5c51b&amp;name=zip00-0001-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s70"></a><a name="section-18"></a><p></p>
<h1>Principal Display Panel - 25 mg - 120-count Bottle Label</h1>
<p class="First">NDC 13913-008-12</p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">Zipsor<span class="Sup">®</span></span><br><span class="Italics">(diclofenac potassium)</span></p>
<p>120 Liquid Filled Capsules</p>
<p><span class="Bold">25 mg</span></p>
<p>Marketed by: Depomed<span class="Sup">®</span></p>
<div class="Figure">
<a name="f05"></a><img alt="25 mg 120-count Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c982eca0-fc41-11e1-a9c8-0002a5d5c51b&amp;name=zip00-0001-04.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ZIPSOR 		
					</strong><br><span class="contentTableReg">diclofenac potassium capsule, liquid filled</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:13913-008</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DICLOFENAC POTASSIUM</strong> (DICLOFENAC) </td>
<td class="formItem">DICLOFENAC POTASSIUM</td>
<td class="formItem">25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SORBITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ISOPROPYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MINERAL OIL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">15mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">X592</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:13913-008-11</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:13913-008-12</td>
<td class="formItem">120  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022202</td>
<td class="formItem">06/16/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Depomed, Inc.
							(937562890)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Mikart, Inc.</td>
<td class="formItem"></td>
<td class="formItem">030034847</td>
<td class="formItem">LABEL(13913-008), PACK(13913-008)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Accucaps Industries Ltd.</td>
<td class="formItem"></td>
<td class="formItem">248441727</td>
<td class="formItem">MANUFACTURE(13913-008)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>374a1e50-a714-43a6-8063-800084d342c0</div>
<div>Set id: c982eca0-fc41-11e1-a9c8-0002a5d5c51b</div>
<div>Version: 7</div>
<div>Effective Time: 20150901</div>
</div>
</div> <div class="DistributorName">Depomed, Inc.</div></p>
</body></html>
